A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116

By sjmartinez • August 8, 2024

Kudo M, Finn RS, Ikeda M, Sung MW, Baron AD, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Meyer T, Nagao S, Saito K, Mody K, Ramji Z, Dubrovsky L, Llovet JM. A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116. Liver Cancer. 2023 Nov 13;13(4):451-458. doi: 10.1159/000535154. PMID: 39114764; PMCID: PMC11305660.

Tags: Hematology/Oncology, Hepatocellular carcinoma, lenvatinib, overall survival, pembrolizumab, Progression-free survival, Publications

Related Posts

p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer

Muss HB, Sun C, Ding YC, Ji J, White TA, Nyrop K, LeBrasseur NK, Neuhausen SL, Mitin N, Sedrak MS. p16INK4a and DNA methylation clocks in[...]

Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization

Levi A, Nasr A, Cui Y, Abbas AA, Arouchian TT, Coveler AL, Pierce TL, Anderson BT, Collisson E, Davelaar J, Lo SK, Gaddam S, Gong[...]

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Bragagnoli AC,[...]